CoronaryAtlas logo
CoronaryAtlas
S100A8
Pathway / Plaque inflammation

S100A8

S100A8protein

S100A8 (calprotectin) drives sterile inflammation and thromboinflammation in acute MI, promoting infarct wall thinning and adverse remodeling.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleCalprotectin subunit; DAMP and plaque-instability marker; infarct wall thinning promoter.
Also acts inMyocardial injury
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000143546

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
59
C — confounder / Type-II
78
A — assay feasibility
68
E — evidence strength
30
T1DI (composite)
8
Specificity differential (R−C)-19.1
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(10)